Publication:

IL-27-driven immunoregulatory pathways in T cells

Loading...
Thumbnail Image

Date

2022-03-17

Published Version

Published Version

Journal Title

Journal ISSN

Volume Title

Publisher

The Harvard community has made this article openly available. Please share how this access benefits you.

Research Projects

Organizational Units

Journal Issue

Citation

Zhang, Huiyuan. 2021. IL-27-driven immunoregulatory pathways in T cells. Doctoral dissertation, Harvard University Graduate School of Arts and Sciences.

Abstract

IL-27 is a pleiotropic cytokine that exert immunoregulatory functions through multiple mechanisms, including induction of IL-10 and multiple co-inhibitory receptors on T cells, but the transcriptional network mediating its diverse functions remains unclear. Combining high-resolution temporal RNA profiling with computational algorithms, we predicted 79 transcription factors induced by IL-27 in T cells. We genetically perturbed 24 TFs and generated an experimentally refined regulatory network for Il10. Our study validated 11 known and discovered 5 positive (Cebpb, Fosl2, Tbx21, Hlx, Atf3) and 2 negative (Irf9, Irf8) Il10 regulators. We report two central regulators, Prdm1 and Maf, that cooperatively drive the expression of signature genes induced by IL-27 in Type 1 regulatory T cells, mediate IL-10 expression in other helper T cells and determine the regulatory phenotype of colonic Foxp3+ regulatory T cells. Prdm1/Maf double-knockout mice develop spontaneous colitis, phenocopying the Il10-deficient mice. Our work provides insights into IL-27 driven transcriptional networks and identifies two shared Il10 regulators that orchestrate immunoregulatory programs across T helper cell subsets. In addition, using the IL-27-induced co-inhibitory gene module as a tool, we discovered LILRB4 as a new co-inhibitory receptor for cancer immunotherapy. Lilrb4-deficient mice are better at controlling tumor growth with improved effector T cell functions in the tumor microenvironment. Transferring Lilrb4-deficient Tregs partially recapitulates the tumor growth control observed in Lilrb4-deficient mice, indicating a Treg-cell intrinsic role of LILRB4 in regulating tumor growth. Moreover, we showed that LILRB4 is preferentially expressed by pathogenic Th17 cells compared to non-pathogenic homeostatic Th17 cells. LILRB4 restrains the encephalitogenicity of Th17 cells in experimental autoimmune encephalomyelitis. Our work demonstrates LILRB4 as a co-inhibitory receptor on T cell that has important function in both cancer and autoimmunity. In summary, our studies provide insights on how IL-27 suppresses autoimmunity and anti-tumor immunity by regulating IL-10 production and expression of known and novel co-inhibitory molecules such as LILRB4 in T cells.

Description

Other Available Sources

Research Data

Keywords

Immunology

Terms of Use

This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service

Endorsement

Review

Supplemented By

Related Stories